At the end of March 2018, Pharmimex, a company, submitted to the Russian Ministry of Industry and Trade an amended application for conclusion of Special Investment Contract (SPIC) to manufacture blood-derived products.
Together with Octapharma, a Swedish company, Pharmimex wants to invest 6.25 billion rubles in the construction of a plant for full-cycle manufacturing of blood-derived products.
This was announced by Alexander Apazov, President of Pharmimex, and confirmed by Alexey Alekhin, Director of Pharmaceutical and Medical Industry Department of the Ministry.
The plant is scheduled for construction in Skopinsky district of Ryazan region. Earlier, Pharmimex made a presentation of this project. It provides for full-cycle manufacturing of human von Willebrand factor/factor VIII concentrates, human factor VIII stabilized by human von Willebrand factor, human factor IX concentrate, intravenous immunoglobulin in 5% and 10% solutions, human albumin solution and human prothrombin complex concentrate under the technology of Octapharma, a Swedish company.
The project also includes the construction of eight blood plasma collection centers and modernization of existing blood transfusion stations with a capacity of 600 tons of plasma a year.